What's the deal with Friday's confrence call??

[anonymous]

The post above are 100% correct.

 

[anonymous]

What a way to layoff good employees.

- Set insanely high goals that destroy morale. All while wrapping yourself in the HHC flag of wanting to put patients first.

- Cram the Challenger sales model in place even though its better suited to B2B sales and does not fit well in traditional pharmaceutical sales much less in the neuro landscape.

- Adjust goals downward a bit to appear you are listening to employees while you're actually just buying time until the end of FY2016 to implement the new sales model.

- Create a new position giving it a fancy name to imply its bigger and badder. Wow I can be a NICM - Neuro Integrated Care Manager which is nothing more than a hospital rep.

- Make the qualifications so high that none of the current MSS's or field trainers can even apply. Note that Challenger conveniently fits the new sales model.

- Layoff 35 current reps and then bring in 23 NICM reps that are more expensive.

- Then sit back and watch how Fycompa growth remains the same because homicidal ideation, levetiracetam, Briviact, and Aptiom are still in the market.

- If the current national sales management truly cared about HHC and Eisai employees they could have simply initiated new training for the respective representatives with epilepsy units in their territories. This would have been a golden chance for employee development and given field trainers a solid chance at promotion without waiting for DSM openings.

- Unfortunately the rumors that have swirling since the hiring of a new sales director and 2 region directors have come to fruition - Eisai neuro reps are not competent and it is their fault Fycompa has not taken off like the Wall Street analysts had hoped.

Well written.. and completely applicable to the Oncology side too.. high goals, blame for lacking sales placed on sales reps called incompetent, horrible challenger model.. very parallel.